Browse > Article
http://dx.doi.org/10.22246/jikm.2022.43.1.41

A Review of Randomized Controlled Trials of Traditional Chinese Medicine Treatment for Coronavirus Disease 2019 Patients  

Park, Ju-heon (Dept. of Korean Medicine, Pusan National University of Korean Medicine)
Yoon, Seong-hoon (Dept. of Korean Medicine, Pusan National University of Korean Medicine)
Lee, In (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University)
Publication Information
The Journal of Internal Korean Medicine / v.43, no.1, 2022 , pp. 41-52 More about this Journal
Abstract
Objectives: The purpose of this study is to investigate recent trends in randomized controlled trials (RCTs) on the treatment of Coronavirus disease 2019 (COVID-19) patients with traditional Chinese medicine (TCM) and analyze the results for the activation of COVID-19 Korean medicine research. Methods: We searched for RCTs published from December 2019 to October 2021 in the Chinese National Knowledge Infrastructure Database (CNKI). The investigation focused on the type of study, the purpose of the study, and the treatment methods. Results: A total of 8 RCTs were selected and analyzed from the 447 searched studies. All studies attempted to observe the effects of herbal medicine. Herbal medicine included granules, decoctions, and intravenous injections. The most frequently used herb type was drugs for clearing away heat and detoxification and releasing the exterior syndrome. In most studies, the effectiveness of TCM treatment of COVID-19 was significantly high. Conclusions: Although more quality studies are needed to support these results, TCM treatment for COVID-19 has been effective. Therefore, we hope that Korean medicine studies on infectious diseases will be actively conducted like TCM and contribute to national health.
Keywords
Coronavirus disease-2019; COVID-19; TCM; randomized controlled trial; RCT;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 중앙방역대책본부.중앙사고수습본부. 코로나바이러스감염증-19 대응 지침(지자체용). 제10-1판. 질병관리청; 2021, p. 95-105.
2 중앙방역대책본부.중앙사고수습본부. 코로나19 국내예방접종완료자 관리 지침. 제3판. 질병관리청; 2021.
3 Hu F, Guo A, Huang L, Yu W, Liu G, Gao X, et al. Jinyinhua Liquid (金银花口服液) at Different Dosage Combined with Western Medicine Conventional Treatment for Common Type COVID-19: A Multicenter Trial of 187 Cases. Journal of Traditional Chinese Medicine 2021;62(6):510-5.
4 Zhang Lh, Zheng X, Bai X, Wang Q, Chen B, Wang H, et al. Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: A national retrospective registry study. Phytomedicine 2021;85:153531.   DOI
5 Guo S, Bao L, Li C, Sun J, Zhao R, Cui X. Antiviral activity of iridoid glycosides extracted from Fructus Gardeniae against influenza A virus by PACT-dependent suppression of viral RNA replication. Scientific Reports 2020;10(1):1897.   DOI
6 Yang M, Yang Sh, Yang M, You Dy. Systematic Review on the Treatment of Novel Coronavirus Pneumonia with Chinese Herbal Lianhua Qingwen. Chinese Journal of Drug Evaluation 2020;37(2):126-30.
7 Zhang H, Wu J, Sun L, Wang T, Lu J. Meta analysis and trial sequential analysis of Lianhua Qingwen treating COVID-19. Prac J Med &Pharm 2020;37(12):1110-4.
8 Pang W, Liu Z, Li N, Li Y, Yang F, Pang B et al. Chinese medical drugs for coronavirus disease 2019: A systematic review and meta-analysis. Integrative Medicine Research 2020;9(3):100477.   DOI
9 Shuang Z, Jun F, Qin X, Tingrong H, Xiaoming X, Daixing Z, et al. Traditional Chinese medicine shenhuang granule in patients with severe/critical COVID-19: A randomized controlled multicenter trial. Phytomedicine 2021;89:153612.   DOI
10 Zhang Y, Lei L, Xu Y, Wei D, Hu F. Clinical Efficacy of Jinyinhua Oral Liquid in the Treatment of 80 Patients with Coronavirus Disease 2019. China Pharmaceuticals 2020;29(09):23-6.
11 Kang BH, Choi YK, Jeon CY, Yang SB. The Effects of Qingfei Paidu Decoction on Coronavirus Disease-19: A Narrative Review. J Int Korean Med 2021;41(3):424-33.
12 Enmozhi SK, Raja K, Sebastine I, Joseph J. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach. Journal of Biomolecular Structure and Dynamics 2021;39(9):3092-8.
13 Hu B, Huang S, Yin L. The cytokine storm and COVID-19. Journal of Medical Virology 2020;93(1):250-6.   DOI
14 Zhijian L, Wei C, Mingqing X, Hua W, Wei X, Cheng X, et al. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial. European Journal of Integrative Medicine 2021;42(prepublish) 101305.   DOI
15 Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 2016;8(8):959-70.   DOI
16 唐陆平, 李伟豪, 袁生. 金银花提取物改善脂多糖致大鼠急性肺损伤作用机制研究. Livestock and Poultry Industry 2019:10:1-3.
17 Sun Y, Lyu W, Li H, Xiao Y, Yang M, Yang H, et al. Qingfei Paidu Decoction (清肺排毒汤) for Treatment of Mild/ Moderate COVID-19 in 295 Cases: A Multi-Centered. Journal of Traditional Chinese Medicine 2021;62(7):599-603.
18 Zhang P, Pan GT. Clinical Study on the Improvement of Inflammatory Cytokines in Critically Ill Patients with COVID-19 Treated by Qingfei Paidu Decoction. Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology 2021;23(2):391-5.
19 이가현. 코로나19 치료제의 현황 및 유효성, 안전성. Journal of Korean Society of Health-System Pharmacists 2021;38(3):377-91.
20 XinYi Z, Lang L, YuLong Z, LiangDong X, Qin X, XiaoFan Z, et al. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial. Phytotherapy research 2021;35(8):4401-10.   DOI
21 Jin W, Lu Y, Zhao W, Tang S, Sang X, Zhang L, et al. The Efficacy of Recommended Treatments with Integrated Chinese and Western Medicine on Coronavirus Disease 2019 (COVID-19) in Sichuan: A Clinical Trial Observation. Pharmacology and Clinics of Chinese Materia Medica 2020;36(6):6-10.
22 Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020;582:289-93.   DOI
23 Lee KE, Jeong SH, Jeong MJ, Choi YM, Song MD, Jang IS. Review on Herbal Medicine Treatment for Late Complications of COVID-19 Patients. J Int Korean Med 2021;42(1):53-66.   DOI
24 Jeong SH, Lee KE, Jeong MJ, Song MD, Jang IS. A review on the treatment of Herbal Medicine for asymptomatically infected COVID-19 patients. J Korean Med 2021;42(1):99-109.
25 Shi H, Guo W, Zhu H, Li M, Ung COL, Hu H, et al. Cost-Effectiveness Analysis of Xiyanping Injection (Andrographolide Sulfonate) for Treatment of Adult Community Acquired Pneumonia: A Retrospective, Propensity Score-Matched Cohort Study. Evidence-Based Complementary and Alternative Medicine 2019:4510591.   DOI
26 Sun H, Xu F, Zhang L, Wei C, Chen J, Wang Q, et al. Study on Clinical Efficacy of Lianhua Qingke Granule in Treatment of Mild and Ordinary COVID-19. Chinese Journal of Experimental Traditional Medical Formulae 2020;26(14):29-34.
27 Fuzimoto AD. An overview of the anti-SARS-CoV-2 properties of Artemisia annua, itsantiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment. Journal of Integrative Medicine 2021 (in press) https://doi.org/10.1016/j.joim.2021.07.003.   DOI
28 Liu M, Yu Q, Yi Y, Xiao H, Putra DF, Ke K, et al. Antiviral activities of Lonicera japonica Thunb. Components against grouper iridovirus in vitro and in vivo. Aquaculture 2020;519:734882.   DOI
29 Qin C, Zhou L, Hu Z, Zhang S, Yang S, MD YT, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Infectious Disease Society of America 2020;71(15):762-8.   DOI
30 Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respitory Medicine 2020;8(4):420-2.   DOI
31 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案 第八版. 中华人民共和国国家卫生健康委员会; 2021.
32 Xiaolong X, Junhua Z, Wenke Z, Zifeng Y, Xuegong Z, Changfeng W, et al. Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study. Annals of palliative medicine 2021;10(5):5146-55.   DOI
33 식품의약품안전처 의약품정책과. 코로나19 치료제.백신 임상시험 등 진행현황. 질병관리본부; 2020.